SEI Investments
AVIR icon

SEI Investments’s Atea Pharmaceuticals AVIR Stock Holding History

SEI Investments’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$88.5K Sell
19,038
-137,346
-88% -$683K ﹤0.01% 3200
2026
Q1 		$841K Buy
+156,384
New +$718K ﹤0.01% 2436
2022
Q1 		– Sell
-54,079
Closed -$483K – 2578
2021
Q4 		$483K Buy
+54,079
New +$843K ﹤0.01% 2120

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

SEI Investments's AVIR Position: Q2 2026 in Review

SEI Investments reduced its Atea Pharmaceuticals (AVIR) stake by 88% in Q2 2026, selling an estimated $683K and leaving 19,038 shares worth $88.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3200.

SEI Investments first reported a position in AVIR in Q4 2021 and has held it in 3 quarters since. The position peaked at $841K in Q1 2026. 124 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

  • SEI Investments held 19,038 shares of Atea Pharmaceuticals worth $88.5K as of Q2 2026.
  • SEI Investments sold 137,346 Atea Pharmaceuticals shares in Q2 2026, an estimated $683K.
  • Atea Pharmaceuticals made up ﹤0.01% of SEI Investments's portfolio in Q2 2026, its #3200 holding.
  • SEI Investments first reported a position in Atea Pharmaceuticals in Q4 2021 and has held it in 3 quarters since.
  • SEI Investments's Atea Pharmaceuticals position peaked at $841K in Q1 2026.
  • 124 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on SEI Investments's 13F filing for Q2 2026, filed 14 Aug 2026.